PTSD, Comorbidities, Gender, and Increased Risk of Cardiovascular Disease

in a Large Military Cohort

David S. Krantz, Ph.D.,^{1, 2} Frances H. Gabbay, Ph.D.,^{2, 3} Elizabeth A. Belleau, Ph.D.,¹

Pablo A. Aliaga, M.S.,^{2, 3} Gary H. Wynn, M.D.,² Murray B. Stein, M.D., M.P.H.,^{4, 5}

Robert J. Ursano, M.D.,² & James A. Naifeh, Ph.D.^{2, 3}

Author Affiliations:

¹ Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD

² Center for the Study of Traumatic Stress, Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD

³ Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD ⁴ Department of Psychiatry and School of Public Health, University of California San Diego, La Jolla, CA

⁵ VA San Diego Healthcare System, San Diego, CA

Running title: PTSD, Comorbidities, and Cardiovascular Disease Risk

Corresponding Author: David S. Krantz, Ph.D., Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda MD, 20814 (david.krantz@usuhs.edu)

ABSTRACT

Importance Posttraumatic stress disorder (PTSD) is a prevalent mental health problem that increases risk of cardiovascular disease (CVD). It is not known whether gender or comorbidities modify associations between PTSD and CVD.

Objective To assess risk of hypertension and atherosclerotic CVD (ASCVD) associated with PTSD in a predominantly young military population, and determine if gender or PTSD comorbidities modify these associations.

Design, setting, and participants Using administrative medical records, this longitudinal, retrospective cohort study assessed relationships of PTSD, gender, comorbidities (metabolic risk factors [MRF], behavioral risk factors [BRF], depression, and sleep disorders) to subsequent hypertension and ASCVD among 863,993 active-duty U.S. Army enlisted soldiers (86.2% male; 93.7% <age 40). Using discrete-time survival analysis, person-months with an initial hypertension diagnosis (n=49,656) were compared to an equal-probability control sample. Separate analyses compared person-months with ASCVD (n=2,427) to an equal-probability control sample.

Main outcomes and measures ICD-9-CM diagnoses of hypertension, ASCVD (coronary artery disease, myocardial infarction, stroke, heart failure), PTSD, MRF (Type 2 diabetes, obesity), BRF (tobacco/alcohol use disorders), depression, and sleep disorders.

Results PTSD was associated with subsequent hypertension (OR=3.0 [95% CI=2.9-3.1]), and ASCVD (OR=2.7 [95% CI=2.2-3.3]). These associations remained significant but were attenuated after adjusting for comorbidities and sociodemographic/service-related variables (Hypertension: OR=1.9 [95% CI=1.8-2.0]; ASCVD: OR=1.4 [95% CI=1.2-1.8]). For hypertension, gender and each comorbidity were significant explanatory variables in multivariable models, and there were significant PTSD interactions with gender, MRF, depression, and sleep disorders. Stratifying separately by gender and presence of each comorbidity, PTSD-hypertension associations were stronger among men, those without MRF, without depression, and without sleep disorders. Standardized risk estimates indicated that predicted hypertension rates for those with vs. without PTSD were higher for men, and for those with vs. without MRF, depression, and sleep disorders. For ASCVD, comorbidities, but not gender, were independent predictors, and associations between PTSD and ASCVD were not modified by gender or comorbidities.

Conclusions and relevance PTSD and comorbidities are independent risk factors for hypertension and ASVD in younger individuals, and gender and comorbid conditions modify PTSD relationships with hypertension. These findings suggest that CVD preventive interventions address PTSD and medical and behavioral comorbidities.

INTRODUCTION

Posttraumatic stress disorder (PTSD) is a stress-related disorder resulting from exposure to trauma and defined by the presence of intrusive thoughts, avoidance of trauma-related stimuli, negative alterations in cognitions and mood, and arousal and stress reactivity.¹ Estimated PTSD lifetime prevalence is 6% in American adults, with a higher lifetime prevalence among military veterans.^{2,3}

PTSD is also a risk factor for the development of cardiovascular disease (CVD), including hypertension and manifestations of atherosclerotic cardiovascular disease (ASCVD) such as coronary heart disease and stroke.⁴⁻⁷ The independent risk associated with PTSD is roughly comparable to that of other major CVD risk factors,⁸⁻¹² and PTSD associations with CVD are present in both men^{9,10,13} and women.¹⁴⁻¹⁶ Since most studies have been conducted in older male veterans,^{9,13} it is unclear whether these associations are present in younger adults or whether there are gender differences in PTSD-CVD associations.^{17,18}

PTSD is a systemic disorder that often co-occurs with medical and behavioral conditions that also are CVD risk factors.¹⁹⁻²⁴ PTSD has a high comorbidity with depression,²⁵⁻²⁷ abdominal obesity,^{28,29} Type 2 diabetes mellitus (T2DM),²⁸ tobacco³⁰ and alcohol use disorders,³¹ and sleep disorders.³²⁻³⁴ Despite prior studies controlling for CVD risk factors,^{9,11,35} it is unclear whether comorbidities account for PTSD-related CVD risk,^{19,36,37} or whether comorbid conditions modify PTSD-related risk.¹⁹ Whether comorbidities contribute to, or modify, CVD risk associated with PTSD has implications for choosing clinical targets and treatments.

The present study examined relationships between PTSD and CVD incidence in a large cohort of male and female servicemembers predominantly under age 40,^{38,39} using electronic medical record diagnostic codes.⁴⁰ Although incidence of hypertension and ASCVD each increase with age,⁴¹ hypertension is more likely to be clinically evident prior to middle age.^{42,43}

Therefore, we separately examined hypertension and ASCVD. We hypothesized that PTSD would be independently associated with subsequent hypertension and ASCVD in this younger population, and that controlling for comorbidities would attenuate but not eliminate this relationship. We also determined whether PTSD-associated risk is modified by gender or by presence of comorbidities.

METHODS

Sample

This longitudinal, retrospective cohort study used data from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS) Historical Administrative Data Study (HADS),³⁹ which integrates all Army and Department of Defense data systems documenting medical outcomes. The HADS includes individual-level person-month records for all soldiers ($n\approx 1.66$ million) on active duty at any point between January 1, 2004, and December 31, 2009, with health data available since 2000. We excluded officers and National Guard and Reserve members and used administrative records from all 863,993 Regular Army enlisted soldiers on active duty between 2004-2009 to select two independent samples: one for hypertension (with no prior or concurrent ASCVD diagnosis) and one for ASCVD (with or without prior/concurrent hypertension). This study was approved by the Uniformed Services University Institutional Review Board and follows Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) cohort study guidelines.

Data were analyzed using a discrete-time survival framework with person-month the unit of analysis^{44,45} and each month of a soldier's career represented as a separate record. To form a sample with hypertension as the sole CVD diagnosis (Hypertension Only), we identified all soldiers receiving a hypertension diagnosis without prior/concurrent ASCVD, selecting for analysis the person-month with first hypertension diagnosis (n=49,656 cases). To reduce computation demands, an equal-probability control sample was selected to be representative of all remaining person-months in the Regular Army enlisted population (n=1,052,151 unweighted person-months). Person-month data were first stratified by gender and service-related variables (rank, time in service, deployment status), then control person-months were selected on a 20:1 ratio to cases and given a weight of 29.7 (inverse probability of selection) to adjust for undersampling. A separate sample of ASCVD cases (with or without prior/concurrent hypertension diagnosis) was selected using an identical process, resulting in 2,427 ASCVD cases (person-months receiving initial ASCVD diagnosis), and 87,722 control person-months, the latter assigned a weight of 362.1 to adjust for under-sampling (Figure 1).

Measures

Cardiovascular disease (CVD) was identified using *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* diagnostic codes⁴⁶ from the Military Health System (MHS) Data Repository and two other MHS databases, providing healthcare encounter information from military and civilian treatment facilities, deployment, and evacuation activities (Supplement, eTable 1). ICD-9-CM codes for CVD (Supplement, eTable 2) were classified as Hypertension Only or ASCVD (atherosclerosis, myocardial infarction, stroke, and/or congestive heart failure). In each sample, cases were identified based on the first personmonth with the CVD diagnosis of interest (Figure 1). Person-month records were right censored after diagnosis.

ICD-9-CM codes were utilized to identify PTSD, depression, and sleep disorders, and create variables for metabolic risk factors (MRF; T2DM and/or obesity), and behavioral risk factors (BRF; tobacco and/or alcohol use disorder) (Supplement, eTable 3). PTSD diagnosis was examined only if documented *prior to* the first person-month with CVD diagnosis (for cases), or

in the sampled person-month (for controls). Gender, race/ethnicity, age, and service-related variables were derived from administrative records (Supplement, eTable1).

Statistical Analyses

Using SAS version 9.4, person-month data were analyzed using discrete-time survival analysis with a logit link function.^{44,45} Associations of PTSD with subsequent hypertension were examined in a univariable logistic regression model, followed by a multivariable model adjusting for sociodemographic and service-related variables, MRF, BRF, depression, and sleep disorders. To determine whether PTSD associations with hypertension differed by gender or presence/absence of comorbidities, two-way interactions of PTSD with gender, MRF, BRF, depression, and sleep disorders were examined in separate covariate-adjusted models. For significant interactions, the sample was stratified by presence/absence of each comorbidity, and the association between PTSD and CVD outcome was examined in a multivariable model within each stratum. The same analytic approach was used to examine associations of PTSD with ASCVD diagnosis.

Logistic regression coefficients were exponentiated to obtain odds ratios (ORs) and 95% CIs. Models included a month/year dummy predictor to control for secular trends; coefficients therefore represent averaged within-month associations assuming no time-varying effects. Expected hypertension and ASCVD rates for those with and without PTSD were derived using full multivariable model coefficients to calculate standardized risk estimates (SREs) for PTSD (yes/no). All SREs are expressed as estimated number of individuals with each CVD endpoint per 1,000 person-years. To reduce Type I error, statistical significance of each Wald χ^2 in the logistic regression models was based on a sample-size-adjusted alpha level⁴⁷ requiring p<0.00048 for hypertension analyses and p<0.00167 for ASCVD analyses.

RESULTS

Sample Characteristics

In the total population, there were 49,656 cases of hypertension only (5.7%) and 2,427 ASCVD cases (0.3%) (*n*=853 ASCVD with prior/concurrent hypertension; *n*=1,574 without hypertension). The weighted hypertension case-control sample (Table 1) was predominantly male; non-Hispanic White; and young (median age=25 years [IQR 22-31]; 93.7% <age 40). A minority had diagnoses of PTSD (1.5%), MRF (4.1%), BRF (11.8%), depression (6.2%), and/or sleep disorders (3.3%). The weighted ASCVD case-control sample (Table 1) was predominantly male; non-Hispanic White; and young (median age=25 years [IQR 22-32], 93.2% <age 40). A minority had diagnoses of PTSD (1.6%), MRF (4.5%), BRF (12.0%), depression (6.4%), and/or sleep disorders (3.6%). Among hypertension cases, 2,201 (4.4%) had prior PTSD (median 10 [IQR 5-20] months between PTSD and hypertension diagnoses). Among ASCVD cases, 107 (4.4%) had prior PTSD (median 10 [IQR 5-29] months between PTSD and ASCVD).

Association of PTSD with Hypertension

Controlling only for historical time, PTSD was associated with increased odds of developing hypertension (OR= 3.0 [95% CI=2.86–3.12]). Hypertension crude rates among those with vs. without PTSD were 59.7 vs. 19.4 per 1,000 person-years. Though attenuated, this association persisted after adjusting for MRF, BRF, depression, sleep disorders, and sociodemographic/service-related variables (OR=1.9 [95% CI=1.81–1.99]). Based on this full model, SREs for hypertension were 31.2 vs. 16.3 per 1,000 person-years among those with vs. without PTSD.

In the full model, there were also significant independent relationships between each risk variable and hypertension (Table 2). Odds of developing hypertension were higher among those with MRF (OR=1.8 [95% CI=1.75–1.86]), BRF (OR=1.3 [95% CI=1.30–1.36]), depression

(OR=1.3 [95% CI=1.23–1.31]), and sleep disorders (OR=1.5 [95% CI=1.48–1.58]), and lower among women than men (OR=0.7 [95% CI=0.64–0.68]).

Modifiers of the PTSD-hypertension relationship were examined using separate multivariable models. There were significant two-way interactions between PTSD and gender (χ^2_1 =43.9, *p*<0.0001), MRF (χ^2_1 =21.3, *p*<0.0001), depression (χ^2_1 =18.9, *p*<0.0001), and sleep disorders (χ^2_1 =17.7, *p*<0.0001). The interaction with BRF was nonsignificant (χ^2_1 =2.7, *p*=0.098).

To understand significant interactions, the sample was stratified separately by gender and each comorbidity, and SREs were calculated within each stratum for individuals with vs. without PTSD. The multivariable association of PTSD with hypertension was significant among men (OR=1.9 [95% CI=1.84–2.03]), and significant but smaller among women (OR=1.4 [95% CI=1.18–1.64]). Among men, standardized hypertension rates were higher for soldiers with vs. without PTSD (SREs=38.7 vs. 20.1 per 1,000 person-years, respectively), as they were among women (SREs=22.6 vs. 16.2) (Figure 2a). Overall, SREs were lower among women relative to men (Supplement, eTables 4-6).

Stratifying by MRF revealed a slightly stronger association between PTSD and hypertension incidence among individuals without (OR=1.9 [95% CI=1.84–2.04]) vs. with MRF (OR=1.7 [95% CI=1.51–1.92]). Among soldiers with MRF, standardized hypertension rates were higher among those with vs. without PTSD (SREs=80.5 vs. 47.4), as they were among soldiers without MRF (SREs=35. 3 vs 18.3). Overall, standardized rates of hypertension were lower among individuals without MRF (Figure 2b).

For depression, the association between PTSD and hypertension was also slightly stronger among individuals without (OR=2.1 [95% CI=1.95-2.22]) vs. with depression (OR=1.8 [95% CI=1.65-1.90]). Among soldiers with depression, standardized hypertension rates were higher among those with vs. without PTSD (SREs=56.6 vs. 32.0), as they were among soldiers

without depression (SREs=38.7 vs. 18.7). Overall, standardized rates of hypertension were lower among individuals without depression (Figure 2c).

PTSD was more strongly associated with hypertension among individuals without (OR=2.0 [95% CI 1.91-2.15]) vs. with sleep disorders (OR=1.6 [95% CI 1.48-1.73]). Among soldiers with sleep disorders, standardized hypertension rates were higher among those with PTSD (SREs=82.3 vs. 51.6), as they were among soldiers without a sleep disorder (SRE=37.3 vs. 18.5). Overall, standardized rates of hypertension were lower among individuals without sleep disorders (Figure 2d).

The pattern of results indicates that standardized risk of hypertension is highest when both PTSD and a comorbidity are present and lowest when both are absent (Figure 2).

Association of PTSD with ASCVD

PTSD was associated with increased odds of ASCVD, controlling only for historical time (OR=2.7 [95% CI=2.25–3.32]). ASCVD crude rates were 2.5 vs. 0.9 per 1,000 person-years for those with vs. without PTSD. Though attenuated, the association persisted after adjusting for MRF, BRF, depression, sleep disorders, and sociodemographic/service-related variables (OR=1.4 [95% CI=1.17–1.79]). Based on this multivariable model, SREs for ASCVD were 1.1 vs. 0.8 for those with vs. without PTSD.

In full multivariable models (Table 3), odds of developing ASCVD were also higher among those with MRF (OR=1.6 [95% CI=1.45–1.87]), BRF (OR=1.9 [95% CI=1.69–2.06]), depression (OR=1.3 [95% CI=1.14–1.49]), and sleep disorders (OR=1.6 [95% CI=1.44–1.86]). The association between gender and ASCVD was nonsignificant using the adjusted alpha level $(\chi^2_1=4.2, p=0.0393)$. Similarly, none of the two-way interactions between PTSD and gender or comorbidity was significant. In a sensitivity analysis adding hypertension to the multivariable ASCVD model, hypertension was significant (OR=3.3 [95% CI=3.00–3.63]), but the PTSD-ASCVD association was no longer significant (OR=1.4 [95% CI=1.10–1.68]; χ^2_I =7.8, p=.0052) (Supplement, eTable 7).

DISCUSSION

This study demonstrates that PTSD is associated with increased risk of both incident hypertension and ASCVD in servicemembers predominantly <40 years old. Comparing those with vs. without PTSD, crude rates (per 1,000 person-years) were 59.7 vs. 19.4 for hypertension and 2.5 vs. 0.9 for ASCVD. PTSD, MRF (obesity and/or T2DM), BRF (tobacco and/or alcohol use disorders), depression, and sleep disorders each independently increased risk of hypertension and ASCVD. Interactions with PTSD indicate further that gender, MRF, depression, and sleep disorders each moderate the relationship between PTSD and hypertension, but not ASCVD.

PTSD and Gender

Consistent with prior research⁴⁻¹² PTSD was associated with risk of subsequent CVD among both men and women.^{9,10,14-16,48} In this relatively young cohort, this risk was higher among men than women, and the association of PTSD with hypertension (but not ASCVD) was stronger among men. One study demonstrated stronger relationships between PTSD and ischemic stroke in men than women;⁵ however, prior studies have not specifically examined interactions between PTSD and gender for hypertension or ASCVD.

PTSD prevalence is higher among women than men.²⁵ CVD risk increases across the lifespan in both genders,⁴³ but is relatively low in premenopausal women.^{49,50} In our predominantly premenopausal female sample, gender differences in PTSD associations with hypertension may be partially explained by protective effects of estrogen⁵¹ and/or lower CVD incidence among younger women.⁵⁰ One study reported a PTSD-hypertension association in

younger women⁵² but did not examine ASCVD. However, it is difficult to compare studies of PTSD and CVD among women because of differences in study population (e.g., active-duty in this study vs. veteran or civilian women; sample age);⁵³⁻⁵⁵ endpoints studied (e.g., single^{14,52} vs. composite CVD diagnoses^{16,56-59}); PTSD assessment method (diagnostic codes vs. questionnaire/interview);¹⁴⁻¹⁶ and follow-up length.^{48,52}

Metabolic Risk Factors, Depression, and Sleep Disorders

Just as PTSD was associated with CVD independent of comorbidities, as in prior studies,^{19,21,22,60} we found that MRF (obesity, T2DM), BRF (tobacco and alcohol use disorders), depression, and sleep disorders were each associated with hypertension and ASCVD, independent of PTSD and of each other.⁶¹ Adjusting for comorbidities attenuated the strength of PTSD associations with CVD; this is consistent with prior evidence that the presence of disorders associated with PTSD (e.g., T2DM) attenuates the association between PTSD and CVD.^{62,63} This effect likely reflects shared variance between PTSD and comorbidities and overlapping mechanisms of disease.^{10, 12, 27, 28, 32-34}

A novel finding is that comorbid conditions modify the relationship between PTSD and hypertension, but not ASCVD; specifically, associations between PTSD and hypertension differed between those with vs. without MRF, depression, and sleep disorders. Results further suggest a cumulative effect of PTSD and comorbidities on standardized hypertension risk. Specifically, absolute risk of hypertension is consistently highest among those with both PTSD and a comorbidity, lowest without PTSD or comorbidity, and fall between those values for individuals with either PTSD or a comorbidity. However, significant interactions between PTSD and comorbid disorders and between PTSD and gender were only found for hypertension and not ASCVD. These results may be partly explained by our predominantly healthy and young population, the relatively low prevalence of ASCVD at younger ages, and a higher likelihood of clinically evident hypertension prior to middle age.^{42,43} Moreover, hypertension may partially mediate the relationship between PTSD and ASCVD, as indicated by the finding that with hypertension included as a covariate in the full ASCVD model, hypertension was associated with the ASCVD outcome, but PTSD was no longer a significant predictor.

Possible mechanisms involved in the direct and interactive effects of PTSD and comorbidities on CVD include PTSD- and stress-related disruptions in HPA axis and other neuroendocrine and metabolic processes; alterations in CNS and autonomic activity; inflammatory/immune changes; and biological effects of sleep disruption.^{10,12,27,28,32-34,37,60,64-67} These physiological processes are associated with PTSD and comorbidities,^{37,66} and there are interactions among these processes, including autonomic nervous system, HPA axis, and inflammatory processes,^{66,68} and additive and/or synergistic relationships among CVD risk factors (e.g., diabetes, smoking, alcohol use).^{61,69} Further research is needed to understand shared disease mechanisms that account for the present findings.

Study Strengths and Limitations

Unlike civilian healthcare, the military healthcare system serves and maintains health and administrative databases for all active-duty soldiers, regardless of socioeconomic level, race, or gender. This contrasts with the Department of Veterans Affairs (VA) system, since some veterans routinely seek care outside the VA. Although our large active-duty enlisted population may increase the likelihood that findings are generalizable to younger, otherwise healthy individuals, selection bias and a relatively low percentage of female soldiers in this sample may also limit generalizability of our findings.

Limitations are also inherent in using diagnostic codes as endpoints. Diagnostic codes may vary between clinicians and are available only if individuals seek care. Some servicemembers with PTSD or other mental disorders believe they do not need treatment or avoid seeking professional help because of stigma;⁷⁰ therefore, it is possible that PTSD and/or depression might have been present but undiagnosed before CVD diagnosis.

As noted previously, associations between gender and ASCVD may not be evident in this younger and healthy cohort. Moreover, the present findings may only generalize to the diagnoses used to quantify hypertension (initial hypertension diagnosis and no current/prior ASCVD) and ASCVD (composite endpoints of initial diagnosis of atherosclerosis, MI, stroke, or congestive heart failure). However, there are several commonalities in pathological mechanisms among the diagnoses used for ASCVD outcome, and positive associations with PTSD have been demonstrated with both single ^{4-6,14} and composite^{16,56-59} CVD endpoints.^{9-11,66} Nevertheless, heterogeneity among diagnoses might have obscured interactions between comorbidities and PTSD for ASCVD.

Conclusions and Clinical Implications

It is notable that we observed the association of PTSD with hypertension, ASCVD, and comorbidities even among relatively healthy, predominantly young soldiers. Thus, physical health consequences of PTSD may begin early, develop subclinically, and have cumulative, long-term effects on morbidity/mortality, quality of life, and the healthcare system.

PTSD is currently defined and treated as a mental health disorder,¹ perhaps because its psychiatric symptoms are overt, debilitating, and readily tied to trauma.^{11,71} However, evidence indicates that PTSD symptoms are part of a broader systemic disorder with wide-ranging

biological and behavioral elements.^{19,21,60,72} The present study reveals important associations and interactions among PTSD, comorbidities, and risk of CVD, and supports a systemic understanding of PTSD.

Current evidence is inconclusive regarding whether treating PTSD using traditional approaches reduces risk of CVD or other comorbid disorders.^{67,73} Empirically-validated psychological/psychiatric treatments for PTSD address and reduce psychological symptomatology, but physical comorbidities associated with PTSD warrant attention from a range of healthcare specialties.^{19,67,73} Thus, the present findings have clinical relevance for identifying individuals at higher risk of CVD, and highlight the need to implement multidisciplinary treatment approaches that address both psychological symptoms of PTSD and associated comorbidities.

ACKNOWLEDGEMENTS

The Army STARRS Team consists of Co-Principal Investigators: Robert J. Ursano, MD (USUHS) and Murray B. Stein, MD, MPH (University of California San Diego and VA San Diego Healthcare System). <u>Site Principal Investigators</u>: James Wagner, PhD (University of Michigan) and Ronald C. Kessler, PhD (Harvard Medical School). <u>Army scientific consultant/liaison</u>: Kenneth Cox, MD, MPH (Office of the Assistant Secretary of the Army (Manpower and Reserve Affairs). <u>Other team members</u>: Pablo A. Aliaga, MS (USUHS); David M. Benedek, MD (USUHS); Laura Campbell-Sills, PhD (University of California San Diego); Carol S. Fullerton, PhD (USUHS); Nancy Gebler, MA (University of Michigan); Meredith House, BA (University of Michigan); Paul E. Hurwitz, MPH (Uniformed Services University); Sonia Jain, PhD (University of California San Diego); Tzu-Cheg Kao, PhD (USUHS); Lisa Lewandowski-Romps, PhD (University of Michigan); Alex Luedtke, PhD (University of Washington and Fred Hutchinson Cancer Research Center); Holly Herberman Mash, PhD (USUHS); James A. Naifeh, PhD (USUHS); Matthew K. Nock, PhD (Harvard University); Nur Hani Zainal, PhD (Harvard Medical School); Nancy A. Sampson, BA (Harvard Medical School); and Alan M. Zaslavsky, PhD (Harvard Medical School).

Funding:

Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 (2009-2015) with the National Institute of Mental Health (NIMH). Subsequently, STARRS-LS was sponsored and funded by the Department of Defense (USUHS grant number HU0001-15-2-0004). Dr. Gabbay was supported by the Defense Health Program (DH) Joint Program Committee 5 (JPC-5) Working Group (Psychological Health and Resilience and PTSD) under Award Numbers HU0001-18-2-0003 and HU0001-21-2-0057. Additional support for manuscript preparation was provided by National Heart Lung and Blood Institute Grant RO1HL085730.

Conflict of Interest Disclosures:

Dr. Stein received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). All other authors report no conflicts of interest.

Disclaimers: The opinions and assertions expressed herein are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences or the Department of Defense. The contents of this publication also are the sole responsibility of the authors and do not necessarily reflect the views, opinions or policies of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. The contents are solely the responsibility of the authors and do not necessarily reflect the views of the NIMH, the Department of the Army, the Department of Defense, or the Department of Veteran Affairs.

REFERENCES

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th ed.* American Psychiatric Association; 2013.

2. Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Social Psychiatry and Psychiatric Epidemiology*. 2016/08/01 2016;51(8):1137-1148. doi:10.1007/s00127-016-1208-5

3. Wisco BE, Nomamiukor FO, Marx BP, Krystal JH, Southwick SM, Pietrzak RH. Posttraumatic Stress Disorder in US Military Veterans: Results From the 2019-2020 National Health and Resilience in Veterans Study. *J Clin Psychiatry*. Feb 22 2022;83(2)doi:10.4088/JCP.20m14029

4. Burg MM, Brandt C, Buta E, et al. Risk for Incident Hypertension Associated With Posttraumatic Stress Disorder in Military Veterans and the Effect of Posttraumatic Stress Disorder Treatment. *Psychosom Med.* Feb/Mar 2017;79(2):181-188. doi:10.1097/PSY.00000000000376

5. Rosman L, Sico JJ, Lampert R, et al. Posttraumatic Stress Disorder and Risk for Stroke in Young and Middle-Aged Adults: A 13-Year Cohort Study. *Stroke*. Nov 2019;50(11):2996-3003. doi:10.1161/STROKEAHA.119.026854

6. Ahmadi N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda R, Ebrahimi R. Posttraumatic stress disorder, coronary atherosclerosis, and mortality. *Am J Cardiol*. Jul 1 2011;108(1):29-33. doi:10.1016/j.amjcard.2011.02.340

7. Turner JH, Neylan TC, Schiller NB, Li Y, Cohen BE. Objective evidence of myocardial ischemia in patients with posttraumatic stress disorder. *Biol Psychiatry*. Dec 1 2013;74(11):861-6. doi:10.1016/j.biopsych.2013.07.012

8. Arenson M, Cohen B. Posttraumatic stress disorder and cardiovascular disease. *PTSD Research Quarterly*. 2017;28(1):1-9.

9. Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. *Am Heart J*. Nov 2013;166(5):806-14. doi:10.1016/j.ahj.2013.07.031

10. Edmondson D, von Känel R. Post-traumatic stress disorder and cardiovascular disease. *The Lancet Psychiatry*. 2017;4(4):320-329. doi:10.1016/s2215-0366(16)30377-7

11. Burg MM, Soufer R. Post-traumatic Stress Disorder and Cardiovascular Disease. *Curr Cardiol Rep.* Oct 2016;18(10):94. doi:10.1007/s11886-016-0770-5

12. Vaccarino V, Bremner JD. Traumatic stress is heartbreaking. *Biol Psychiatry*. Dec 1 2013;74(11):790-2. doi:10.1016/j.biopsych.2013.10.002

13. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. *Psychosom Med.* Jul 2008;70(6):668-76. doi:10.1097/PSY.0b013e31817bccaf

14. Ebrahimi R, Lynch KE, Beckham JC, et al. Association of Posttraumatic Stress Disorder and Incident Ischemic Heart Disease in Women Veterans. *JAMA Cardiol.* Jun 1 2021;6(6):642-651. doi:10.1001/jamacardio.2021.0227

15. Kubzansky LD, Koenen KC, Jones C, Eaton WW. A prospective study of posttraumatic stress disorder symptoms and coronary heart disease in women. *Health Psychol.* Jan 2009;28(1):125-30. doi:10.1037/0278-6133.28.1.125

16. Sumner JA, Kubzansky LD, Elkind MS, et al. Trauma exposure and posttraumatic stress disorder symptoms predict onset of cardiovascular events in women. *Circulation*. Jul 28 2015;132(4):251-9. doi:10.1161/CIRCULATIONAHA.114.014492

17. Cohen BE. Exploring Posttraumatic Stress Disorder as a Cardiovascular Risk Factor in Women Veterans: The Heart of the Matter. *JAMA Cardiol*. Jun 1 2021;6(6):651-652. doi:10.1001/jamacardio.2021.0236

18. Lewis TT. Trauma and Posttraumatic Stress Disorder: Emerging Risk Factors for Cardiovascular Disease in Women? *Circulation*. Jul 28 2015;132(4):227-9. doi:10.1161/circulationaha.115.017432

19. Krantz DS, Shank LM, Goodie JL. Post-traumatic stress disorder (PTSD) as a systemic disorder: Pathways to cardiovascular disease. *Health Psychol*. Oct 2022;41(10):651-662. doi:10.1037/hea0001127

20. Freedland KE, Carney RM. Depression as a risk factor for adverse outcomes in coronary heart disease. *BMC Med.* May 15 2013;11:131. doi:10.1186/1741-7015-11-131

21. Flory JD, Yehuda R. Is PTSD a systemic disorder? *Psychiatric Times*. 2018;35(4):19-21.

22. Schnurr PP, Wachen JS, Green BL, Kaltman S. Trauma exposure, PTSD, and physical health. *Handbook of PTSD: Science and practice, 2nd ed.* The Guilford Press; 2014:502-521.

23. Hall MH, Brindle RC, Buysse DJ. Sleep and cardiovascular disease: Emerging opportunities for psychology. *Am Psychol*. Nov 2018;73(8):994-1006. doi:10.1037/amp0000362

24. Kwok CS, Kontopantelis E, Kuligowski G, et al. Self-Reported Sleep Duration and Quality and Cardiovascular Disease and Mortality: A Dose-Response Meta-Analysis. *J Am Heart Assoc.* Aug 7 2018;7(15):e008552. doi:10.1161/JAHA.118.008552

25. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. Dec 1995;52(12):1048-60. doi:10.1001/archpsyc.1995.03950240066012

26. Davidson KW, Alcántara C, Miller GE. Selected psychological comorbidities in coronary heart disease: Challenges and grand opportunities. *Am Psychol*. Nov 2018;73(8):1019-1030. doi:10.1037/amp0000239

27. Bremner JD. *Posttraumatic stress disorder : from neurobiology to treatment*. Wiley Blackwell; 2016.

28. Farr OM, Sloan DM, Keane TM, Mantzoros CS. Stress- and PTSD-associated obesity and metabolic dysfunction: a growing problem requiring further research and novel treatments. *Metabolism.* Dec 2014;63(12):1463-8. doi:10.1016/j.metabol.2014.08.009

29. Kubzansky LD, Bordelois P, Jun HJ, et al. The weight of traumatic stress: a prospective study of posttraumatic stress disorder symptoms and weight status in women. *JAMA Psychiatry*. Jan 2014;71(1):44-51. doi:10.1001/jamapsychiatry.2013.2798

30. Fu SS, McFall M, Saxon AJ, et al. Post-traumatic stress disorder and smoking: a systematic review. *Nicotine Tob Res.* Nov 2007;9(11):1071-84. doi:10.1080/14622200701488418

31. Dworkin ER, Bergman HE, Walton TO, Walker DD, Kaysen DL. Co-Occurring Post-Traumatic Stress Disorder and Alcohol Use Disorder in U.S. Military and Veteran Populations. *Alcohol Res.* 2018;39(2):161-169.

32. Krakow BJ, Ulibarri VA, Moore BA, McIver ND. Posttraumatic stress disorder and sleep-disordered breathing: a review of comorbidity research. *Sleep Med Rev.* Dec 2015;24:37-45. doi:10.1016/j.smrv.2014.11.001

33. Koffel E, Khawaja IS, Germain A. Sleep Disturbances in Posttraumatic Stress Disorder: Updated Review and Implications for Treatment. *Psychiatr Ann*. Mar 2016;46(3):173-176. doi:10.3928/00485713-20160125-01

34. Li M, Zhang XW, Hou WS, Tang ZY. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. *Int J Cardiol*. Oct 20 2014;176(3):1044-7. doi:10.1016/j.ijcard.2014.07.284

35. Belleau EA. Posttraumatic stress disorder and sleep disorders: Effects on cardiovascular disease risk in active duty U.S. Army enlisted Servicemembers. Defense Technical Information Center, Technical Report Accession# AD1186109. Doctoral Thesis, Uniformed Services University of the Health Sciences. Accessed 9-24-2020.

https://apps.dtic.mil/sti/pdfs/AD1186109.pdf

36. Scherrer JF, Salas J, Cohen BE, et al. Comorbid Conditions Explain the Association Between Posttraumatic Stress Disorder and Incident Cardiovascular Disease. *J Am Heart Assoc*. Feb 19 2019;8(4):e011133. doi:10.1161/jaha.118.011133

37. Ursano RJ, Stein MB. From Soldier's Heart to Shared Genetic Risk: PTSD and Cardiovascular Disease. *Am J Psychiatry*. Nov 1 2022;179(11):785-787. doi:10.1176/appi.ajp.20220778

38. Naifeh JA, Mash HBH, Stein MB, Fullerton CS, Kessler RC, Ursano RJ. The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS): progress toward understanding suicide among soldiers. *Mol Psychiatry*. Jan 2019;24(1):34-48. doi:10.1038/s41380-018-0197-z

39. Ursano RJ, Colpe LJ, Heeringa SG, Kessler RC, Schoenbaum M, Stein MB. The Army study to assess risk and resilience in servicemembers (Army STARRS). *Psychiatry*. Summer 2014;77(2):107-19. doi:10.1521/psyc.2014.77.2.107

40. Judkins JL, Moore BA, Collette TL, Hale WJ, Peterson AL, Morissette SB. Incidence Rates of Posttraumatic Stress Disorder Over a 17-Year Period in Active Duty Military Service Members. *J Trauma Stress*. Dec 2020;33(6):994-1006. doi:10.1002/jts.22558

41. Zhou B, Danaei G, Stevens GA, et al. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. *The Lancet*. 2019;394(10199):639-651. doi:10.1016/S0140-6736(19)31145-6

42. Ållen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. *Jama*. Feb 5 2014;311(5):490-7. doi:10.1001/jama.2013.285122

43. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. Feb 22 2022;145(8):e153e639. doi:10.1161/cir.00000000001052

44. Singer JD, Willett JB. *Applied longitudinal data analysis: Modeling change and event occurrence*. Oxford University Press; 2003.

45. Willett JB, Singer JD. Investigating onset, cessation, relapse, and recovery: Why you should, and how you can, use discrete-time survival analysis to examine event occurrence. *Journal of Consulting and Clinical Psychology*. Dec 1993;61(6):952-965.

46. National Center for Health Statistics CDC. *ICD-9-CM*: *International classification of diseases, 9th revision, clinical modification.* 5th ed. 1997.

47. Good IJ. C140. Standardized tail-area prosabilities. *Journal of Statistical Computation and Simulation*. 1982/12/01 1982;16(1):65-66. doi:10.1080/00949658208810607

48. Roberts AL, Kubzansky LD, Chibnik LB, Rimm EB, Koenen KC. Association of Posttraumatic Stress and Depressive Symptoms With Mortality in Women. *JAMA Network Open*. 2020;3(12):e2027935-e2027935. doi:10.1001/jamanetworkopen.2020.27935

49. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. *Circulation*. 2020/12/22 2020;142(25):e506e532. doi:10.1161/CIR.00000000000912 50. Bello NA, Bairey Merz CN, Cheng S. A Scientific Imperative as Seen Through a Sharpened Lens: Sex, Gender, and the Cardiovascular Condition. *Circ Res.* Feb 18 2022;130(4):433-435. doi:10.1161/circresaha.122.320825

51. Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biol Sex Differ*. Oct 24 2017;8(1):33. doi:10.1186/s13293-017-0152-8

52. Sumner JA, Kubzansky LD, Roberts AL, et al. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middle-aged women. *Psychological Medicine*. Nov 2016;46(15):3105-3116. doi:10.1017/S0033291716001914

53. Olff M, Langeland W, Draijer N, Gersons BP. Gender differences in posttraumatic stress disorder. *Psychol Bull.* Mar 2007;133(2):183-204. doi:10.1037/0033-2909.133.2.183

54. Resnick EM, Mallampalli M, Carter CL. Current challenges in female veterans' health. *J Womens Health (Larchmt)*. Sep 2012;21(9):895-900. doi:10.1089/jwh.2012.3644

55. Hourani L, Williams J, Bray R, Kandel D. Gender differences in the expression of PTSD symptoms among active duty military personnel. *J Anxiety Disord*. Jan 2015;29:101-8. doi:10.1016/j.janxdis.2014.11.007

56. Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans. *Am J Geriatr Psychiatry*. Mar 2016;24(3):192-200. doi:10.1016/j.jagp.2014.12.003

57. Remch M, Laskaris Z, Flory J, Mora-McLaughlin C, Morabia A. Post-Traumatic Stress Disorder and Cardiovascular Diseases: A Cohort Study of Men and Women Involved in Cleaning the Debris of the World Trade Center Complex. *Circ Cardiovasc Qual Outcomes*. Jul 2018;11(7):e004572. doi:10.1161/circoutcomes.117.004572

58. Jordan HT, Miller-Archie SA, Cone JE, Morabia A, Stellman SD. Heart disease among adults exposed to the September 11, 2001 World Trade Center disaster: Results from the World Trade Center Health Registry. *Preventive Medicine*. 2011/12/01/ 2011;53(6):370-376. doi:10.1016/j.ypmed.2011.10.014

59. Gradus J, L., Dóra Körmendiné F, Elisabeth S, et al. Associations between stress disorders and cardiovascular disease events in the Danish population. *BMJ Open*. 2015;5(12):e009334. doi:10.1136/bmjopen-2015-009334

60. Koenen KC, Sumner JA, Gilsanz P, et al. Post-traumatic stress disorder and cardiometabolic disease: improving causal inference to inform practice. *Psychol Med.* Jan 2017;47(2):209-225. doi:10.1017/s0033291716002294

61. Hernesniemi JA, Tynkkynen J, Havulinna AS, et al. Significant interactions between traditional risk factors affect cardiovascular risk prediction in healthy general population. *Annals of Medicine*. 2015/01/02 2015;47(1):53-60. doi:10.3109/07853890.2014.970570

62. Scherrer JF, Salas J, Lustman PJ, et al. The Role of Obesity in the Association Between Posttraumatic Stress Disorder and Incident Diabetes. *JAMA Psychiatry*. 2018;75(11):1189-1198. doi:10.1001/jamapsychiatry.2018.2028

63. Vaccarino V, Goldberg J, Magruder KM, et al. Posttraumatic stress disorder and incidence of type-2 diabetes: a prospective twin study. *J Psychiatr Res.* Sep 2014;56:158-64. doi:10.1016/j.jpsychires.2014.05.019

64. Hori H, Kim Y. Inflammation and post-traumatic stress disorder. *Psychiatry Clin Neurosci*. Apr 2019;73(4):143-153. doi:10.1111/pcn.12820

65. Michopoulos V, Vester A, Neigh G. Posttraumatic stress disorder: A metabolic disorder in disguise? *Exp Neurol*. Oct 2016;284(Pt B):220-229. doi:10.1016/j.expneurol.2016.05.038

66. O'Donnell CJ, Schwartz Longacre L, Cohen BE, et al. Posttraumatic Stress Disorder and Cardiovascular Disease: State of the Science, Knowledge Gaps, and Research Opportunities. *JAMA Cardiol*. Oct 1 2021;6(10):1207-1216. doi:10.1001/jamacardio.2021.2530

67. van den Berk Clark C, Kansara V, Fedorova M, et al. How does PTSD treatment affect cardiovascular, diabetes and metabolic disease risk factors and outcomes? A systematic review. *Journal of Psychosomatic Research*. 2022/06/01/ 2022;157:110793.

doi:10.1016/j.jpsychores.2022.110793

68. Brudey C, Park J, Wiaderkiewicz J, Kobayashi I, Mellman TA, Marvar PJ. Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.* 2015/08/15 2015;309(4):R315-R321. doi:10.1152/ajpregu.00343.2014

69. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. *Diabetes Care*. Nov 2009;32 Suppl 2(Suppl 2):S429-31. doi:10.2337/dc09-S354

70. Naifeh JA, Colpe LJ, Aliaga PA, et al. Barriers to Initiating and Continuing Mental Health Treatment Among Soldiers in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). *Mil Med.* Sep 2016;181(9):1021-32. doi:10.7205/milmed-d-15-00211

71. Soufer R, Krantz DS. The Interaction of Biology and Emotion: Uncovering a New Phenotype of Nonobstructive Coronary Artery Disease. *Biol Psychiatry*. Apr 1 2022;91(7):606-608. doi:10.1016/j.biopsych.2022.01.005

72. McFarlane AC. Post-traumatic stress disorder is a systemic illness, not a mental disorder: is Cartesian dualism dead? *Med J Aust*. Apr 3 2017;206(6):248-249. doi:10.5694/mja17.00048

73. Bourassa KJ, Hendrickson RC, Reger GM, Norr AM. Posttraumatic Stress Disorder Treatment Effects on Cardiovascular Physiology: A Systematic Review and Agenda for Future Research. *J Trauma Stress*. Apr 2021;34(2):384-393. doi:10.1002/jts.22637

Table 1 Distribution of Sociodemographic/Service-Related Variables and PTSD and Comorbidity Diagnoses Among Regular Army Enlisted

Soldiers During 2004–2009^a

-		ension Only ^b	Arteriosclerotic CVD (ASCVD) ^c					
-	Cases Weighted total popula			population	Ca		Weighted total population	
-	(person-months)		(person-months) ^c		(person-months)		(person-months)) ^d	
	N ^d	% ⁰ /0 ^e	$ m N^{f}$	⁰∕₀ g	\mathbf{N}^{h}	⁰∕₀ ⁱ	$ m N^{f}$	⁰∕₀ g
Gender								
Female	5,638	11.4	4,130,300	13.8	335	13.8	4,247,832	13.8
Male	44,018	88.6	25,741,886	86.2	2,092	86.2	26,637,746	86.2
Race/ethnicity								
White, not Hispanic	25,106	50.6	18,023,070	60.3	1,227	50.6	18,470,651	59.8
Black	17,267	34.8	6,589,174	22.1	813	33.5	6,979,438	22.6
Hispanic	4,338	8.7	1,196,236	4.0	82	3.4	1,251,774	4.1
Asian	1,722	3.5	589,793	2.0	73	3.0	611,979	2.0
Other	1,223	2.5	3,473,913	11.6	232	9.6	3,571,736	11.6
Current age (years)								
≤ 20 [°]	2,241	4.5	4,629,144	15.5	112	4.6	4,634,667	15.0
21–24	8,692	17.5	9,168,494	30.7	253	10.4	9,311,001	30.1
25–29	10,011	20.2	7,006,278	23.5	263	10.8	7,246,099	23.5
30–34	8,652	17.4	4,056,296	13.6	305	12.6	4,222,457	13.7
35–39	10,262	20.7	3,108,310	10.4	512	21.1	3,362,736	10.9
≥ 40	9,798	19.7	1,903,665	6.4	982	40.5	2,108,618	6.8
Time in service (years)	,		, ,				, ,	
1–2	7,557	15.2	8,574,475	28.7	286	11.8	8,631,782	27.9
3–4	8,074	16.3	6,732,441	22.5	245	10.1	6,885,455	22.3
5–10	12,639	25.5	8,091,893	27.1	457	18.8	8,366,190	27.1
≥ 10	21,386	43.1	6,473,378	21.7	1,439	59.3	7,002,151	22.7
Rank	,		, ,		,		, ,	
E1–E2	3,328	6.7	3,809,892	12.8	148	6.1	3,833,431	12.4
E3	4,191	8.4	4,361,812	14.6	139	5.7	4,409,121	14.3
E4	11,629	23.4	8,361,325	28.0	339	14.0	8,566,299	27.7
E5–E6	17,821	35.9	9,790,378	32.8	873	36.0	10,217,531	33.1
Е7-Е9	12,687	25.5	3,548,779	11.9	928	38.2	3,859,195	12.5

Deployed								
Ever	29,329	59.1	17,696,700	59.2	1,367	56.3	18,394,393	59.6
Never	20,327	40.9	12,175,486	40.8	1,060	43.7	12,491,184	40.4
PTSD								
Yes	2,201	4.4	442,238	1.5	107	4.4	508,460	1.6
No	47,455	95.6	29,429,948	98.5	2,320	95.6	30,377,118	98.4
MRF								
Yes	5,018	10.1	1,233,326	4.1	293	12.1	1,396,090	4.5
No	44,638	89.9	28,638,861	95.9	2,134	87.9	29,489,487	95.5
BRF								
Yes	9,065	18.3	3,538,791	11.8	568	23.4	3,714,367	12.0
No	40,591	81.7	26,333,395	88.2	1,859	76.6	27,171,211	88.0
Depression								
Yes	5,444	11.0	1,841,658	6.2	309	12.7	1,967,822	6.4
No	44,212	89.0	28,030,528	93.8	2,118	87.3	28,917,755	93.6
Sleep disorders								
Yes	4,544	9.2	977,314	3.3	315	13.0	1,118,401	3.6
No	45,112	90.8	28,894,873	96.7	2,112	87.0	29,767,176	96.4
Total	49,656	100	29,872,186	100	2,427	100	30,885,578	100

Note. ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; BRF = behavioral risk factors; HADS = Army STARRS

Historical Administrative Data Study; MRF = metabolic risk factors; PTSD = posttraumatic stress disorder

^a These samples are representative of Regular Army enlisted soldiers who were on active duty at any point during 2004-2009. and are subsets of the total HADS person-months.

^b The Hypertension Only sample consisted of cases (i.e., all soldiers with any ICD-9-CM diagnosis of hypertension and no current or prior

ASCVD diagnosis; 49,656 hypertension case person-months) and controls (i.e., a representative sample of all other person months; n=1,052,151 unweighted control person-months). All control person-months in the Hypertension Only sample were assigned a weight of 19.7 to adjust for under-sampling.

^c Cases as a percent of the total population of soldiers. Calculation of % includes cases (i.e., person-months with a first CVD diagnosis) and weighted control person-months. Weighted person-months for cases as a percent of the total population of person-months.

^d The ASCVD sample consisted of cases (i.e., all soldiers with any ICD-9-CM diagnosis of atherosclerosis, myocardial infarction, stroke, and/or congestive heart failure; n=2,427 ASCVD case person-months) and controls (i.e., a representative sample of all other person months; n=87,722 unweighted control person-months). All control person-months in the ASCVD sample were assigned a weight of 362.1 to adjust for undersampling.

^d The number of person-months in the population with a first hypertension diagnosis.

^e Percent of all person-months with a first hypertension diagnosis.

^fThe weighted total number of person-months in the population (i.e., includes both cases person-months and weighted control person-months).

^g Weighted percent of the total population.

^h The number of person-months in the population with a first ASCVD diagnosis.

ⁱ Percent of all person-months with a first ASCVD diagnosis.

Table 2

Univariable and Multivariable Associations of First PTSD Diagnosis with Subsequent Hypertension Diagnosis among Regular Army Enlisted

Soldiers^a

		Нуре	rtension ^b		
	U	nivariable ^c	Multivariable ^d		
	OR	95% CI	OR	95% CI	
Gender					
Female	0.8	[0.78, 0.82]	0.7	[0.64, 0.68]	
Male	1.0	_	1.0	_	
χ^{2} 1	245.4, p	< 0.0001*	802.0, p	< 0.0001*	
Age (years)					
≤ 20	0.2	[0.22, 0.24]	0.2	[0.21, 0.24]	
21–24	0.4	[0.43, 0.46]	0.4	[0.42, 0.45]	
25–29	0.7	[0.65, 0.69]	0.7	[0.63, 0.68]	
30–34	1.0	_	1.0	_	
35–39	1.6	[1.51, 1.60]	1.5	[1.47, 1.56]	
\geq 40	2.4	[2.35, 2.49]	2.3	[2.19, 2.34]	
χ^{2} 5	21,827.0	, <i>p</i> < 0.0001*	8,313.5,	<i>p</i> < 0.0001*	
Race					
White Non-Hispanic	1.0	_	1.0	_	
Black	1.9	[1.86, 1.94]	1.6	[1.55, 1.62]	
Hispanic	0.9	[0.87, 0.93]	0.9	[0.87, 0.93]	
Asian	1.0	[1.00, 1.09]	1.0	[0.96, 1.06]	
Other	1.5	[1.43, 1.60]	1.1	[1.07, 1.20]	
χ^2 4	4,847.2,	<i>p</i> < 0.0001*	2,308.0,	<i>p</i> < 0.0001*	
Time in service (years)		-		-	
1–2	0.6	[0.56, 0.58]	0.7	[0.69, 0.76]	
3–4	0.8	[0.75, 0.79]	1.0	[0.93, 1.0]	
5–10	1.0	_	1.0	_	
≥ 10	2.1	[2.10, 2.19]	1.0	[0.96, 1.02]	
χ^2_3	13,366.0	, <i>p</i> < 0.0001*	195.7, p	< 0.0001*	
			-		

ת 1					
Rank E1–E2		0.6	[0 60 0 65]	1 1	[1 00 1 21]
E1-E2 E3		0.6 0.7	[0.60, 0.65]	1.1 1.1	[1.09, 1.21]
E3 E4		0.7	[0.67, 0.72]	1.1 1.0	[1.08, 1.19]
E4 E5–E6		1.0	- [1 20 1 24]	1.0 0.7	-
E3–E0 E7–E9		1.5 2.6	[1.28, 1.34]		[0.72, 0.76]
E/-E9	2		[2.52, 2.65]	0.8	[0.72, 0.78]
5 1 1	χ^2 4	10,178.	1, <i>p</i> < 0.0001*	449.6,	<i>p</i> < 0.0001*
Deployed ^e					
Yes		1.0	[0.95, 0.99]	0.7	[0.72, 0.75]
No		1.0	—	1.0	—
	χ^2 1	10.6, <i>p</i>	= 0.0011	917.2,	<i>p</i> < 0.0001*
MRF					
Yes		2.6	[2.54, 2.69]	1.8	[1.75, 1.86]
No		1.0	-	1.0	—
	χ^2_1	4,138.8	, <i>p</i> < 0.0001*	1,462.6	5, p < 0.0001*
BRF	70		. 1	,	· 1
Yes		1.6	[1.59,1.67]	1.3	[1.30, 1.36]
No		1.0		1.0	
	χ^2 1	1.690.8	, <i>p</i> < 0.0001*	535.1.	p < 0.0001*
Depression	<i>7</i> 0 1	_,		,1	
Yes		1.8	[1.79, 1.90]	1.3	[1.23, 1.31]
No		1.0		1.0	_
	χ^2 1		, <i>p</i> < 0.0001*		p < 0.0001*
Sleep disorders	\mathcal{L}^{1}	1,790.0	<i>, p</i> • 0.0001	210.0,]	0.0001
Yes		2.9	[2.83, 3.01]	1.5	[1.48, 1.58]
No		1.0		1.0	
110	χ^2	-	n < 0.0001*	-	n < 0.0001*
PTSD	χI	4,399.3	, <i>p</i> < 0.0001*	020.2,	<i>p</i> < 0.0001*
Yes		2.0	[2 86 2 12]	1.0	[1 91 1 00]
r es No		3.0 1.0	[2.86, 3.12]	1.9 1.0	[1.81, 1.99]
INO	2		-		-
	χ^{2} 1	2,475.6	, <i>p</i> < 0.0001*	710.4,	<i>p</i> < 0.0001*

Note. ASCVD = arteriosclerotic CVD; CVD = cardiovascular disease; MRF = medical risk factors; BRF = behavioral risk factors; HADS = Army STARRS Historical Administrative Data Study; PTSD = posttraumatic stress disorder; STARRS = Army Study to Assess Risk and Resilience in Servicemembers.

*p < 0.00048 (based on sample size-adjusted alpha level).

^a These samples are representative of Regular Army enlisted soldiers who were on active duty at any point during 2004-2009.

^b This sample included 49,656 Hypertension Only cases and 1,052,151 unweighted control person-months. All control person-months were assigned a weight of 29.7 to adjust for under-sampling.

^c Adjusted only for historical time (using a dummy predictor variable for calendar month and year).

^d Model includes all of the variables listed plus historical time (using a dummy predictor variable for calendar month and year).

^e Before rounding, the univariable result for Deployed (yes vs. no) is: OR=0.97 [95% CI=0.95–0.99].

Table 3

		Arterioscl	erotic CV	rotic CVD ^b		
	Univariable ^c		Ми	ıltivariable ^d		
	OR	95% CI	OR	95% CI		
Gender						
Female	1.0	[0.90, 1.13]	0.9	[0.78, 0.99]		
Male	1.0		1.0	_		
χ^2 1	0.0, p =	0.9133	4.2, p =	0.0393		
Age (years)	. 1					
≤ 20	0.3	[0.27, 0.42]	0.3	[0.24, 0.40]		
21–24	0.4	[0.32, 0.44]	0.4	[0.31, 0.46]		
25–29	0.5	[0.43, 0.59]	0.5	[0.41, 0.59]		
30–34	1.0	_	1.0	_		
35–39	2.1	[1.83, 2.43]	2.1	[1.85, 2.48]		
≥ 40	6.4	[5.67, 7.33]	6.3	[5.44, 7.25]		
χ^{2} 5	3,056.1, <i>p</i> < 0.0001*		1,257.2	, <i>p</i> < 0.0001*		
Race		-		-		
White Non-Hispanic	1.0	_	1.0	_		
Black	1.8	[1.61, 1.93]	1.2	[1.09, 1.32]		
Hispanic	1.0	[0.85, 1.13]	1.0	[0.84, 1.12]		
Asian	1.0	[0.79, 1.23]	1.0	[0.77, 1.20]		
Other	1.8	[1.43, 2.29]	1.1	[0.84, 1.34]		
χ^2_4	183.9, p	<i>v</i> < 0.0001*	17.6, p	= 0.0015*		
Time in service (years)	-		-			
1–2	0.6	[0.53, 0.71]	0.8	[0.60, 1.00]		
3–4	0.7	[0.56, 0.76]	1.0	[0.80, 1.16]		
5–10	1.0	_	1.0	_		
≥ 10	3.8	[3.41, 4.21]	0.9	[0.79, 1.05]		
χ^2_3	1,513.1	p < 0.0001*	5.7, <i>p</i> =	0.1290		

Univariable and Multivariable Associations of First PTSD Diagnosis with Subsequent ASCVD Diagnosis among Regular Army Enlisted Soldiers^a

	1.0	[0.81, 1.19]	1.6	[1.25, 2.11]
	0.8	[0.66, 0.97]	1.2	[0.94, 1.55]
	1.0	_	1.0	_
	2.2	[1.90, 2.45]	1.0	[0.83, 1.16]
	6.1	[5.37, 6.88]	1.0	[0.79, 1.17]
$\chi^2 4$	1,342.7	7, $p < 0.0001*$	14.2, p	= 0.0067
,,		· 1	1	
	0.9	[0.80, 0.94]	0.7	[0.65, 0.78]
	1.0	_	1.0	_
χ^2	12.6. p	= 0.0004*	57.0. p	< 0.0001*
70 -			I I I I I	
	2.9	[2.56, 3.27]	1.6	[1.45, 1.87]
	1.0		1.0	
χ^2	291.0.	<i>p</i> < 0.0001*	58.6, p	< 0.0001*
70 -		L	1	
	2.3	[2.06, 2.50]	1.9	[1.69, 2.06]
	1.0		1.0	
χ^2	279.6,	<i>p</i> < 0.0001*	148.8,	<i>p</i> < 0.0001*
70 -	/	L		1
	2.1	[1.90, 2.41]	1.3	[1.14, 1.49]
	1.0	_	1.0	_
χ^2	154.3.	p < 0.0001*	15.5. p	< 0.0001*
10 -		L	1	
	4.0	[3.58, 4.55]	1.6	[1.44, 1.86]
	1.0	_	1.0	_
γ^2	514.6.	p < 0.0001*	55.3. n	< 0.0001*
<i>N</i> 1	,	r 5.000 -	,p	
	2.7	[2.25, 3.32]	1.4	[1.17, 1.79]
	1.0	- J	1.0	
	χ^{2}_{1} χ^{2}_{1} χ^{2}_{1} χ^{2}_{1}	$\begin{array}{c} 1.0\\ 2.2\\ 6.1\\ \chi^{2}4\\ 1,342.7\\ 0.9\\ 1.0\\ \chi^{2}1\\ 12.6, p\\ 2.9\\ 1.0\\ \chi^{2}1\\ 291.0, p\\ 2.3\\ 1.0\\ \chi^{2}1\\ 279.6, p\\ 2.1\\ 1.0\\ \chi^{2}1\\ 154.3, p\\ 4.0\\ 1.0\\ \chi^{2}1\\ 514.6, p\\ 2.7\end{array}$	1.0 - 2.2 [1.90, 2.45] 6.1 [5.37, 6.88] $\chi^{2}4$ 1,342.7, $p < 0.0001^{*}$ 0.9 [0.80, 0.94] 1.0 - $\chi^{2}1$ 12.6, $p = 0.0004^{*}$ 2.9 [2.56, 3.27] 1.0 - $\chi^{2}1$ 291.0, $p < 0.0001^{*}$ 2.3 [2.06, 2.50] 1.0 - $\chi^{2}1$ 279.6, $p < 0.0001^{*}$ 2.1 [1.90, 2.41] 1.0 - $\chi^{2}1$ 154.3, $p < 0.0001^{*}$ 4.0 [3.58, 4.55] 1.0 - $\chi^{2}1$ 514.6, $p < 0.0001^{*}$ 2.7 [2.25, 3.32]	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Notes. ASCVD = arteriosclerotic CVD; CVD = cardiovascular disease; MRF = medical risk factors; BRF = behavioral risk factors; HADS = Army STARRS Historical Administrative Data Study; PTSD = posttraumatic stress disorder; STARRS = Army Study to Assess Risk and Resilience in Servicemembers.

*p < 0.00167 (based on sample size-adjusted alpha level).

^a These samples are representative of Regular Army enlisted soldiers who were on active duty at any point during 2004-2009.

^b This sample included 2,427 ASCVD cases and 87,722 unweighted control person-months. All control person-months were assigned a weight of 362.1 to adjust for under-sampling.

^c Adjusted only for historical time (using a dummy predictor variable for calendar month and year).

^d Model includes all of the variables listed plus historical time (using a dummy predictor variable for calendar month and year).

Figure 1. Flowchart representing the selection of two samples of Regular Army enlisted soldiers based on ICD-9-CM CVD diagnoses: (1) all person-months with a first hypertension diagnosis (without prior/concurrent ASCVD), and an equal-probability sample of control person-months (assigned a weight of 29.7 to adjust for under-sampling); and (2) all person-months with a first ASCVD diagnosis (with or without prior/concurrent hypertension diagnosis) and an equal-probability sample of control person-months (assigned a weight of 362.1). ASCVD=atherosclerotic cardiovascular disease; CVD=cardiovascular disease; ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification.

31




Figure 2. Standardized risk estimates of hypertension among individuals with and without posttraumatic stress disorder (PTSD) based on multivariable logistic regression analyses conducted within strata defined by gender and presence of other conditions and disorders. Panel (a): Gender (men vs. women); Panel (b): individuals with vs. without a metabolic risk factor (MRF; T2DM and/or obesity); Panel (c): individuals vs. without depression; and Panel (d): individuals with vs. without a sleep disorder.

